RT Journal Article
SR Electronic
T1 <sup>18</sup>F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 835
OP 841
DO 10.2967/jnumed.123.265622
VO 64
IS 6
A1 Leupe, Hannes
A1 Ahenkorah, Stephen
A1 Dekervel, Jeroen
A1 Unterrainer, Marcus
A1 Van Cutsem, Eric
A1 Verslype, Chris
A1 Cleeren, Frederik
A1 Deroose, Christophe M.
YR 2023
UL http://jnm.snmjournals.org/content/64/6/835.abstract
AB Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with 68Ga or 64Cu is currently the gold standard in clinical practice. However, widespread implementation of 68Ga imaging is often hampered by practical and economic issues related to 68Ge/68Ga generators. 18F offers several advantages to tackle these issues. Recent developments in radiochemistry have allowed a shift from 68Ga toward 18F labeling, leading to promising clinical translations of 18F-labeled SSAs, such as Gluc-Lys-[18F]FP-TOCA, [18F]F-FET-βAG-TOCA, [18F]AlF-NOTA-octreotide, [18F]SiTATE, and [18F]AlF-NOTA-JR11. This review gives an update of currently available clinical data regarding 18F-labeled SSA tracers and provides justification for the clinical application of this class of tracers.